Calibrating CARs

Switchable CAR T cells could target solid tumors safely

Instead of focusing on how to turn chimeric antigen receptor (CAR) T cells off when things go wrong, a group at the California Institute for Biomedical Research (Calibr) has engineered a universal CAR T cell that is only switched on when it's wanted. By designing the system to dial out side effects and dial in tissue specificity, the researchers believe the new type of CAR T cells will be both powerful and safe enough to use against solid tumors.

That's been one of the main limitations of CAR T cells, whose dramatic impact has so far been limited to blood cancers. The most advanced CAR T cells in development - from Juno Therapeutics Inc., partners Novartis AG and the University of Pennsylvania - target CD19 to treat acute lymphoblastic leukemia (ALL), and other disclosed CAR T cell therapies in the clinic are for leukemias, lymphomas and hematologic malignancies.

However, while patients can live with the B cell depletion that sometimes comes with targeting CD19, most other tumor antigens are also expressed on healthy tissues that would lead to much more severe toxicities if targeted. CAR T cell therapies can also cause cytokine release syndrome, an inflammatory reaction caused by release of cytokines that can be severe or fatal if not quickly reversed.

Conventional CAR T cells target tumors directly via an antibody fragment against a tumor antigen, joined to an intracellular domain that triggers T cell activation. Several companies are developing strategies to prevent adverse events that involve shutting down the T

Read the full 2501 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers